Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(05): 756-757
DOI: 10.4103/ijmpo.ijmpo_95_19
Practitioner Section

Oral Mucositis with Abiraterone Acetate: A Therapeutic Dilemma

Shaunak Valame
Department of Medical Oncology, Indraprastha Apollo Hospital, New Delhi, India
,
G Chandra
Department of Medical Oncology, Indraprastha Apollo Hospital, New Delhi, India
,
Dipanjan Panda
Department of Medical Oncology, Indraprastha Apollo Hospital, New Delhi, India
,
Atul Sharma
Department of Medical Oncology, Indraprastha Apollo Hospital, New Delhi, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Mucositis is a common complication of cancer treatment. Mucositis has varied etiology. Here, we describe a case of 71-year-old male with metastatic castrate-resistant carcinoma prostate who developed mucositis with the use of targeted therapy, and this particular scenario led to the therapeutic dilemma.

Keywords

Abiraterone acetate - metastatic castration-resistant prostate cancer - mucositis


Publication History

Received: 10 April 2019

Accepted: 20 October 2019

Article published online:
17 May 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017; 377: 352-60
    CrossrefPubMedSearch in Google Scholar
  • 2 Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152-60
    CrossrefPubMedSearch in Google Scholar
  • 3 Scott LJ. Abiraterone acetate: A review in metastatic castration-resistant prostrate cancer. Drugs 2017; 77: 1565-76
    CrossrefPubMedSearch in Google Scholar
  • 4 Ramudo-Cela L, Balea-Filgueiras J, Vizoso-Hermida JR, Martín-Herranz I. Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience. J Oncol Pharm Pract 2017; 23: 615-9
    CrossrefPubMedSearch in Google Scholar
  • 5 Al-Ansari S, Zecha JA, Barasch A, de Lange J, Rozema FR, Raber-Durlacher JE. Oral mucositis induced by anticancer therapies. Curr Oral Health Rep 2015; 2: 202-11
    CrossrefPubMedSearch in Google Scholar
  • 6 Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B. et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol 2018; 36: 1389-95
    CrossrefPubMedSearch in Google Scholar